At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Effect of Inhaled Aclidinium Bromide (LAS34273) 200 ug on Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe COPD
In Brief
A Phase 3 clinical trial evaluating Aclidinium Bromide and Placebo for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 181 participants across 52 sites in 2 countries.
Detailed Summary
This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo.
Study Details
Timeline
Interventions
Aclidinium Bromide, 200μg. Once daily oral inhalation.
Dose matched placebo, once daily oral inhalation.